DNA damage phenotype

Aliases

DNA damage by aldehydes and alcohol

No related entities found.

Mentioned in (43)

Papers in which this entity is mentioned.

• Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types. (2026)
• FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy. (2025)
• Multigenerational cell tracking of DNA replication and heritable DNA damage. (2025)
• Chromosomal instability as a driver of cancer progression. (2025)
• Transcription start sites experience a high influx of heritable variants fueled by early development. (2025)
• Gastrulation-stage alcohol exposure induces similar rates of craniofacial malformations in male and female C57BL/6J mice. (2024)
• ENPP1 Immunobiology as a Therapeutic Target. (2023)
• Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. (2023)
• Towards understandings of serine/arginine-rich splicing factors. (2023)
• Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. (2022)
• Transcriptomic analyses of gastrulation-stage mouse embryos with differential susceptibility to alcohol. (2021)
• Loss of tumor protein 53 protects against alcohol-induced facial malformations in mice and zebrafish. (2021)
• Macrophage Polarization States in the Tumor Microenvironment. (2021)
• Best practices for variant calling in clinical sequencing. (2020)
• DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. (2020)
• Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. (2020)
• Designing combination therapies with modeling chaperoned machine learning. (2019)
• RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. (2019)
• A Compendium of Mutational Signatures of Environmental Agents. (2019)
• The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer. (2018)
• MutationalPatterns: comprehensive genome-wide analysis of mutational processes. (2018)
• EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. (2018)
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. (2017)
• Gene-environment interactions in development and disease. (2017)
• Copy-number signatures and mutational processes in ovarian carcinoma (2017)
• Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. (2016)
• New insights into the generation and role of de novo mutations in health and disease. (2016)
• Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. (2016)
• Evolutionary Insights into RNA trans-Splicing in Vertebrates. (2016)
• The Genetics of Fetal Alcohol Spectrum Disorders. (2016)
• A germline polymorphism of thymine DNA glycosylase induces genomic instability and cellular transformation. (2014)
• Break-induced replication is a source of mutation clusters underlying kataegis. (2014)
• Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. (2014)
• Involvement of p53 in the repair of DNA double strand breaks: multifaceted Roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). (2014)
• Ewing sarcoma protein: a key player in human cancer. (2013)
• RNA splicing: a new player in the DNA damage response. (2013)
• Mutational processes molding the genomes of 21 breast cancers. (2012)
• Detectable clonal mosaicism from birth to old age and its relationship to cancer. (2012)
• Massive genomic rearrangement acquired in a single catastrophic event during cancer development. (2011)
• BRCA1 and BRCA2: different roles in a common pathway of genome protection. (2011)
• Functional consequences of developmentally regulated alternative splicing. (2011)
• 3' end mRNA processing: molecular mechanisms and implications for health and disease. (2008)
• MDM2 and MDM4: p53 regulators as targets in anticancer therapy. (2007)

Merged raw entities (2)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.